Across its top 20 institutional holders, PHIO's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 4/100, avg. turnover score 44/100).

Quarterly Activity

Recent Activity

+$622.3K

Total Buy Value

$81.1K

Total Sell Value

New buy12

Trim0

Add5

Sold out6

Net Buyers

Net Sellers

Smart Money Convergence

PHIO does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/stocks/PHIO

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-21

2026-07-21

Phio Pharmaceuticals expanded its board to six members and appointed dermatologist Dr. R. Todd Plott as a director, effective July 20, 2026. Dr. Plott, a board-certified dermatologist and former FDA advisory committee member with over 30 years of experience, will also join the board's Governance Committee. The company issued a press release on July 21, 2026, announcing the appointment. Dr. Plott will receive standard non-employee director compensation and enter into an indemnification agreement.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

71880W501

FAQ

Who are the top institutional investors holding PHIO PHARMACEUTICALS CORP (PHIO)?

Major stakeholders currently include Geode Capital Management, LLC ($179.6K), Jane Street Group, LLC ($145.4K), Vanguard Capital Management LLC ($97.4K). Based on the latest 13F filings, there are a total of 24 tracked investment funds and institutions maintaining positions in PHIO.

What is the overall institutional sentiment toward PHIO recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $432.6K, driven by 17 managers accumulating shares while 6 reduced their exposure.

Which institutions have been selling or reducing their PHIO positions?

In the latest period, 0 funds trimmed their holdings, and 6 managers completely exited their positions. The aggregate reported sell value was $81.1K.

Are there any notable investors adding PHIO to their portfolios?

Yes, buying activity remains notable. 12 institutions opened new positions in {ticker}, and 5 existing holders added to their shares. The total reported buy value for the quarter amounted to $622.3K.

Related Stocks

Trending Institutional Adds

The most-added stocks by 13F institutions this quarter

MSFT

Microsoft CORP

Institutions Holding

6,151

Total reported value

$2.1T

3246 13F institutions increased their position this quarter

View detail

AMZN

Amazon.com INC

Institutions Holding

5,958

Total reported value

$1.5T

3029 13F institutions increased their position this quarter

View detail

NVDA

Nvidia CORP

Institutions Holding

5,766

Total reported value

$3.0T

2744 13F institutions increased their position this quarter

View detail

Developer Access

Access PHIO's institutional ownership data programmatically:

REST API

curl https://alphasmo.com/api/v1/market/stock/PHIO

CLI

npx alphasmo stocks get PHIO

Full API & MCP documentation →